The global drug discovery services market size is projected to garner significant growth from 2023 to 2033. According to the research report published by FMI, the global market is anticipated to surpass a valuation of US$ 19.7 billion in 2023. It is likely to hit a valuation of US$ 76.5 billion by 2033. The market is projected to exhibit a captivating CAGR of 14.5% from 2023 to 2033.
New drugs are continuously required to address the various unmet medical needs. Several diseases, including neurodegenerative, cancer, rare genetics, and cardiovascular diseases still lack effective treatment. The emergence of new diseases is spiraling the demand for new drugs. Drug discovery services are expected to increase multifold due to the growing development and discovery of novel drugs.
Drug discovery requires substantial resources and time. As drug discovery becomes complex, the demand for specialized expertise across various scientific disciplines rises. Experts from toxicology, medicinal chemistry, pharmacology, and formulation development usually engage in discovering new drugs. Outsourcing these services can reduce costs and time for research institutions and pharmaceutical companies. The outsourced drug delivery services market provides access to specialized infrastructure and expertise, without any high investments.
Several pharmaceutical, biopharmaceutical, and medical device businesses devote significant resources to developing new medications and technologies. The pharmaceutical sector spends a lot of money on research and development (R&D). The research and development pharmaceutical industry brings high-quality, innovative goods to market. The top pharma companies are enhancing their R&D efficiencies through massive R&D investments to reap long-term benefits.
Initiatives for rare diseases and orphan drug research drive new income streams in the market. However, stringent rules regulating drug research and animal testing may limit market expansion to some extent. Moreover, drug discovery service companies still need to deal with the problem of a scarcity of trained employees.
| Attributes | Details |
|---|---|
| Drug Discovery Services Market Share (2022) | US$ 17.5 billion |
| Drug Discovery Services Market Share (2023) | US$ 19.7 billion |
| Drug Discovery Services Market Share (2033) | US$ 76.5 billion |
| Drug Discovery Services Market Share (2023 to 2033) | 14.5% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
In 2022, the global drug discovery services market size stood at US$ 17.5 billion. The market share is expanding rapidly due to the rising market dynamics for pharmaceuticals. Technical developments are likely to amplify market development. An increase in the adoption of novel methodologies for discovery is observed. Escalating demand for generic medications and an increase in patients expiring, all contribute to rising drug distribution.
The increased research and development in the pharmaceutical industry bolster the market’s growth prospects. The evolution of the healthcare industry combined with the rise in demand for generic medications augments the demand for drug discovery services. The rising geriatric population, and technical developments in drug discovery services, all accelerate the market's growth. Additionally, the growing pharmaceutical sector and a surge in contract development services aid market expansion. Growing manufacturing companies that are promoting drug discovery operations boost sales of drug discovery services.
Other factors that positively influence drug discovery trends include:
Pharmaceutical companies occupy lion’s share in the global market. The segment accounted for 42% market share in 2022. Pharmaceutical companies rely on market trends and intelligence to devise drug discovery strategies. They collaborate with research institutions and Contract Research Organizations (CROs) to research specific ailments for target audiences. Therefore, the increasing funding from pharmaceutical companies for new drug discoveries bolsters market growth. Moreover, the development and launch of novel drugs give a boost to market growth.
In terms of market share, the Hit-to-lead identification method is the dominant segment. A hit compound is a molecule that exhibits appropriate activity in a screening assay. Researchers use a slew of methods to find the hit molecule. Although, the conventional technique of high-throughput screening is the standard one. Therefore, the lead optimization segment is expected to see increased demand as technology advances and new state-of-the-art facilities arise.
The medicinal chemistry services segment is predicted to increase at a high-double-digit CAGR throughout the forecast period.
The trend of pharmaceutical companies outsourcing research and development services is growing. The expanding drug discovery and development activities and R&D investments are driving the market forward.
During the projection period, the biological services segment in the drug discovery market is expected to increase at a high CAGR.
Small molecules accounted for a huge portion of the drug discovery services market in 2022. The biologics segment is predicted to expand at a remarkable CAGR in the coming years. The growing use of small-molecule medications to treat chronic diseases surges the demand for these drugs.
Small-molecule pharmaceuticals, even though, dominate the global pharmaceutical market, biologics, biosimilars, and large-molecule drugs are gaining market share. Primarily due to the introduction of new biologic-based treatments and rising earnings from current biologics. In addition, biologics and biosimilars necessitate more specialized testing services than small molecules at each level. Therefore, in the next few years, the growing demand for outsourcing these activities to CROs is likely to fuel the expansion of the market.
Oncology dominated the drug discovery services market in terms of therapeutic areas. It is predicted to continue to do so throughout the forecast period. The segment accounted for an impressive 39.7% market share in 2022. Cancer medicines are in high demand due to increasing cancer cases worldwide. This is likely to make the segment a prominent shareholder in the next years.
Principal Consultant
North America is a global leader in research and development spending in the pharmaceutical industry. The region accounted for a massive 35.2% market share in 2022. The region is also an outsize market for bulk medications and ready-to-use dosage forms.
The United States accounted for 24.1% market share in 2022. The region’s market works as a free economy, with transparent trading practices and anti-competitive actions restricted. Since biologics is more expensive, the United States has a lot of room for biosimilars. As a result, the United States drug discovery services market is one of the primary competitors for biosimilars.
Remicade, Enbrel, Rituximab, Adalimumab, Infliximab, Etanercept, Darbepoetin Alpha, and other drugs are among the popular players in the United States. As a result of the factors mentioned above, the market is expected to grow rapidly over the forecast period. The progressive increase in regional healthcare spending aids new pharmaceutical technology advancements.
The global drug discovery services market is competitive, with Laboratory Corporation of America Holdings (United States), Charles River Laboratories International Inc. (United States), WuXi AppTec (China), and Thermo Fisher Scientific Inc. (United States) collectively accounting for a large portion of the market. The United States-based company, Laboratory Corporation of America Holdings, is a prominent player in the global market.
These key players in the global drug discovery market focus on a broad spectrum of clients. They emphasize incorporating modern and advanced technology-enabled solutions. Increasing investments in joint ventures & partnerships are likely to be prevalent as key strategies. Extensive quality systems and processes contribute to the growth of businesses operating in the market. These companies may use organic and inorganic growth techniques, such as acquisitions and expansions, to tap into new demographics.
Several drugs are pending approval from the United States Food and Drug Administration (FDA).
Anticipated Drug Approvals in 2023:
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The market attained a revenue of US$ 17.5 billion in 2022.
Increasing funding and reimbursement initiatives increases market demand.
Pharmaceutical companies offer lucrative opportunities.
The hit-to-lead identification method is the dominant segment.
The market is estimated to secure a valuation of US$ 19.7 billion in 2023.
1. Executive Summary | Drug Discovery Services Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Process 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Process, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Process, 2023 to 2033 5.3.1. Target Selection 5.3.2. Target Validation 5.3.3. Hit-to-Lead Identification 5.3.4. Lead Optimization 5.3.5. Candidate Validation 5.4. Y-o-Y Growth Trend Analysis By Process, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Process, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033 6.3.1. Chemistry Services 6.3.2. Biology Services 6.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033 7.3.1. Small Molecules Drugs 7.3.2. Biologics Drugs 7.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapeutic Area 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By Therapeutic Area, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapeutic Area, 2023 to 2033 8.3.1. Neurology 8.3.2. Infectious and Immune System Diseases 8.3.3. Digestive System Diseases 8.3.4. Oncology 8.3.5. Other Therapeutic Area 8.4. Y-o-Y Growth Trend Analysis By Therapeutic Area, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By Therapeutic Area, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 9.1. Introduction / Key Findings 9.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022 9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033 9.3.1. Pharmaceutical & Biotechnology Companies 9.3.2. Academic Institutes 9.3.3. Manufacturing 9.3.4. Other End Users 9.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022 9.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 10.1. Introduction 10.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 10.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 10.3.1. North America 10.3.2. Latin America 10.3.3. Europe 10.3.4. South Asia 10.3.5. East Asia 10.3.6. Oceania 10.3.7. MEA 10.4. Market Attractiveness Analysis By Region 11. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. The USA 11.2.1.2. Canada 11.2.2. By Process 11.2.3. By Type 11.2.4. By Drug Type 11.2.5. By Therapeutic Area 11.2.6. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Process 11.3.3. By Type 11.3.4. By Drug Type 11.3.5. By Therapeutic Area 11.3.6. By End User 11.4. Key Takeaways 12. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Brazil 12.2.1.2. Mexico 12.2.1.3. Rest of Latin America 12.2.2. By Process 12.2.3. By Type 12.2.4. By Drug Type 12.2.5. By Therapeutic Area 12.2.6. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Process 12.3.3. By Type 12.3.4. By Drug Type 12.3.5. By Therapeutic Area 12.3.6. By End User 12.4. Key Takeaways 13. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Germany 13.2.1.2. United Kingdom 13.2.1.3. France 13.2.1.4. Spain 13.2.1.5. Italy 13.2.1.6. Rest of Europe 13.2.2. By Process 13.2.3. By Type 13.2.4. By Drug Type 13.2.5. By Therapeutic Area 13.2.6. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Process 13.3.3. By Type 13.3.4. By Drug Type 13.3.5. By Therapeutic Area 13.3.6. By End User 13.4. Key Takeaways 14. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. India 14.2.1.2. Malaysia 14.2.1.3. Singapore 14.2.1.4. Thailand 14.2.1.5. Rest of South Asia 14.2.2. By Process 14.2.3. By Type 14.2.4. By Drug Type 14.2.5. By Therapeutic Area 14.2.6. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Process 14.3.3. By Type 14.3.4. By Drug Type 14.3.5. By Therapeutic Area 14.3.6. By End User 14.4. Key Takeaways 15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. China 15.2.1.2. Japan 15.2.1.3. South Korea 15.2.2. By Process 15.2.3. By Type 15.2.4. By Drug Type 15.2.5. By Therapeutic Area 15.2.6. By End User 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Process 15.3.3. By Type 15.3.4. By Drug Type 15.3.5. By Therapeutic Area 15.3.6. By End User 15.4. Key Takeaways 16. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. Australia 16.2.1.2. New Zealand 16.2.2. By Process 16.2.3. By Type 16.2.4. By Drug Type 16.2.5. By Therapeutic Area 16.2.6. By End User 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Process 16.3.3. By Type 16.3.4. By Drug Type 16.3.5. By Therapeutic Area 16.3.6. By End User 16.4. Key Takeaways 17. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 17.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 17.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 17.2.1. By Country 17.2.1.1. GCC Countries 17.2.1.2. South Africa 17.2.1.3. Israel 17.2.1.4. Rest of MEA 17.2.2. By Process 17.2.3. By Type 17.2.4. By Drug Type 17.2.5. By Therapeutic Area 17.2.6. By End User 17.3. Market Attractiveness Analysis 17.3.1. By Country 17.3.2. By Process 17.3.3. By Type 17.3.4. By Drug Type 17.3.5. By Therapeutic Area 17.3.6. By End User 17.4. Key Takeaways 18. Key Countries Market Analysis 18.1. USA 18.1.1. Pricing Analysis 18.1.2. Market Share Analysis, 2022 18.1.2.1. By Process 18.1.2.2. By Type 18.1.2.3. By Drug Type 18.1.2.4. By Therapeutic Area 18.1.2.5. By End User 18.2. Canada 18.2.1. Pricing Analysis 18.2.2. Market Share Analysis, 2022 18.2.2.1. By Process 18.2.2.2. By Type 18.2.2.3. By Drug Type 18.2.2.4. By Therapeutic Area 18.2.2.5. By End User 18.3. Brazil 18.3.1. Pricing Analysis 18.3.2. Market Share Analysis, 2022 18.3.2.1. By Process 18.3.2.2. By Type 18.3.2.3. By Drug Type 18.3.2.4. By Therapeutic Area 18.3.2.5. By End User 18.4. Mexico 18.4.1. Pricing Analysis 18.4.2. Market Share Analysis, 2022 18.4.2.1. By Process 18.4.2.2. By Type 18.4.2.3. By Drug Type 18.4.2.4. By Therapeutic Area 18.4.2.5. By End User 18.5. Germany 18.5.1. Pricing Analysis 18.5.2. Market Share Analysis, 2022 18.5.2.1. By Process 18.5.2.2. By Type 18.5.2.3. By Drug Type 18.5.2.4. By Therapeutic Area 18.5.2.5. By End User 18.6. United Kingdom 18.6.1. Pricing Analysis 18.6.2. Market Share Analysis, 2022 18.6.2.1. By Process 18.6.2.2. By Type 18.6.2.3. By Drug Type 18.6.2.4. By Therapeutic Area 18.6.2.5. By End User 18.7. France 18.7.1. Pricing Analysis 18.7.2. Market Share Analysis, 2022 18.7.2.1. By Process 18.7.2.2. By Type 18.7.2.3. By Drug Type 18.7.2.4. By Therapeutic Area 18.7.2.5. By End User 18.8. Spain 18.8.1. Pricing Analysis 18.8.2. Market Share Analysis, 2022 18.8.2.1. By Process 18.8.2.2. By Type 18.8.2.3. By Drug Type 18.8.2.4. By Therapeutic Area 18.8.2.5. By End User 18.9. Italy 18.9.1. Pricing Analysis 18.9.2. Market Share Analysis, 2022 18.9.2.1. By Process 18.9.2.2. By Type 18.9.2.3. By Drug Type 18.9.2.4. By Therapeutic Area 18.9.2.5. By End User 18.10. India 18.10.1. Pricing Analysis 18.10.2. Market Share Analysis, 2022 18.10.2.1. By Process 18.10.2.2. By Type 18.10.2.3. By Drug Type 18.10.2.4. By Therapeutic Area 18.10.2.5. By End User 18.11. Malaysia 18.11.1. Pricing Analysis 18.11.2. Market Share Analysis, 2022 18.11.2.1. By Process 18.11.2.2. By Type 18.11.2.3. By Drug Type 18.11.2.4. By Therapeutic Area 18.11.2.5. By End User 18.12. Singapore 18.12.1. Pricing Analysis 18.12.2. Market Share Analysis, 2022 18.12.2.1. By Process 18.12.2.2. By Type 18.12.2.3. By Drug Type 18.12.2.4. By Therapeutic Area 18.12.2.5. By End User 18.13. Thailand 18.13.1. Pricing Analysis 18.13.2. Market Share Analysis, 2022 18.13.2.1. By Process 18.13.2.2. By Type 18.13.2.3. By Drug Type 18.13.2.4. By Therapeutic Area 18.13.2.5. By End User 18.14. China 18.14.1. Pricing Analysis 18.14.2. Market Share Analysis, 2022 18.14.2.1. By Process 18.14.2.2. By Type 18.14.2.3. By Drug Type 18.14.2.4. By Therapeutic Area 18.14.2.5. By End User 18.15. Japan 18.15.1. Pricing Analysis 18.15.2. Market Share Analysis, 2022 18.15.2.1. By Process 18.15.2.2. By Type 18.15.2.3. By Drug Type 18.15.2.4. By Therapeutic Area 18.15.2.5. By End User 18.16. South Korea 18.16.1. Pricing Analysis 18.16.2. Market Share Analysis, 2022 18.16.2.1. By Process 18.16.2.2. By Type 18.16.2.3. By Drug Type 18.16.2.4. By Therapeutic Area 18.16.2.5. By End User 18.17. Australia 18.17.1. Pricing Analysis 18.17.2. Market Share Analysis, 2022 18.17.2.1. By Process 18.17.2.2. By Type 18.17.2.3. By Drug Type 18.17.2.4. By Therapeutic Area 18.17.2.5. By End User 18.18. New Zealand 18.18.1. Pricing Analysis 18.18.2. Market Share Analysis, 2022 18.18.2.1. By Process 18.18.2.2. By Type 18.18.2.3. By Drug Type 18.18.2.4. By Therapeutic Area 18.18.2.5. By End User 18.19. GCC Countries 18.19.1. Pricing Analysis 18.19.2. Market Share Analysis, 2022 18.19.2.1. By Process 18.19.2.2. By Type 18.19.2.3. By Drug Type 18.19.2.4. By Therapeutic Area 18.19.2.5. By End User 18.20. South Africa 18.20.1. Pricing Analysis 18.20.2. Market Share Analysis, 2022 18.20.2.1. By Process 18.20.2.2. By Type 18.20.2.3. By Drug Type 18.20.2.4. By Therapeutic Area 18.20.2.5. By End User 18.21. Israel 18.21.1. Pricing Analysis 18.21.2. Market Share Analysis, 2022 18.21.2.1. By Process 18.21.2.2. By Type 18.21.2.3. By Drug Type 18.21.2.4. By Therapeutic Area 18.21.2.5. By End User 19. Market Structure Analysis 19.1. Competition Dashboard 19.2. Competition Benchmarking 19.3. Market Share Analysis of Top Players 19.3.1. By Regional 19.3.2. By Process 19.3.3. By Type 19.3.4. By Drug Type 19.3.5. By Therapeutic Area 19.3.6. By End User 20. Competition Analysis 20.1. Competition Deep Dive 20.1.1. Laboratory Corporation of America Holdings 20.1.1.1. Overview 20.1.1.2. Product Portfolio 20.1.1.3. Profitability by Market Segments 20.1.1.4. Sales Footprint 20.1.1.5. Strategy Overview 20.1.1.5.1. Marketing Strategy 20.1.2. Charles River Laboratories International Inc. 20.1.2.1. Overview 20.1.2.2. Product Portfolio 20.1.2.3. Profitability by Market Segments 20.1.2.4. Sales Footprint 20.1.2.5. Strategy Overview 20.1.2.5.1. Marketing Strategy 20.1.3. Genscript Biotech Corporation 20.1.3.1. Overview 20.1.3.2. Product Portfolio 20.1.3.3. Profitability by Market Segments 20.1.3.4. Sales Footprint 20.1.3.5. Strategy Overview 20.1.3.5.1. Marketing Strategy 20.1.4. Thermo Fisher Scientific Inc. 20.1.4.1. Overview 20.1.4.2. Product Portfolio 20.1.4.3. Profitability by Market Segments 20.1.4.4. Sales Footprint 20.1.4.5. Strategy Overview 20.1.4.5.1. Marketing Strategy 20.1.5. Pharmaron Beijing Co., Ltd. 20.1.5.1. Overview 20.1.5.2. Product Portfolio 20.1.5.3. Profitability by Market Segments 20.1.5.4. Sales Footprint 20.1.5.5. Strategy Overview 20.1.5.5.1. Marketing Strategy 20.1.6. Evotec SE 20.1.6.1. Overview 20.1.6.2. Product Portfolio 20.1.6.3. Profitability by Market Segments 20.1.6.4. Sales Footprint 20.1.6.5. Strategy Overview 20.1.6.5.1. Marketing Strategy 20.1.7. Eurofins Scientific SE 20.1.7.1. Overview 20.1.7.2. Product Portfolio 20.1.7.3. Profitability by Market Segments 20.1.7.4. Sales Footprint 20.1.7.5. Strategy Overview 20.1.7.5.1. Marketing Strategy 20.1.8. Pharmaceutical Product Development, Inc. 20.1.8.1. Overview 20.1.8.2. Product Portfolio 20.1.8.3. Profitability by Market Segments 20.1.8.4. Sales Footprint 20.1.8.5. Strategy Overview 20.1.8.5.1. Marketing Strategy 20.1.9. Piramal Enterprises Limited 20.1.9.1. Overview 20.1.9.2. Product Portfolio 20.1.9.3. Profitability by Market Segments 20.1.9.4. Sales Footprint 20.1.9.5. Strategy Overview 20.1.9.5.1. Marketing Strategy 20.1.10. Syngene International Limited 20.1.10.1. Overview 20.1.10.2. Product Portfolio 20.1.10.3. Profitability by Market Segments 20.1.10.4. Sales Footprint 20.1.10.5. Strategy Overview 20.1.10.5.1. Marketing Strategy 21. Assumptions & Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
Drug Discovery Services Market
